Evidence map›Paper›PMID 24391952›Full record

ArticlePloS one2013

Celiac anti-type 2 transglutaminase antibodies induce phosphoproteome modification in intestinal epithelial Caco-2 cells.

Gaetana Paolella, Ivana Caputo, Anna Marabotti, Marilena Lepretti, Anna Maria Salzano, Andrea Scaloni, Monica Vitale, Nicola Zambrano, Daniele Sblattero, Carla Esposito

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Gaetana PaolellaDepartment of Chemistry and Biology, University of Salerno, Salerno, Italy.
Ivana CaputoDepartment of Chemistry and Biology, University of Salerno, Salerno, Italy ; European Laboratory for the Investigation of Food-Induced Diseases (ELFID), University "Federico II", Naples, Italy.
Anna MarabottiDepartment of Chemistry and Biology, University of Salerno, Salerno, Italy.
Marilena LeprettiDepartment of Chemistry and Biology, University of Salerno, Salerno, Italy.
Anna Maria SalzanoProteomics and Mass Spectrometry Laboratory, ISPAAM, National Research Council, Naples, Italy.
Andrea ScaloniProteomics and Mass Spectrometry Laboratory, ISPAAM, National Research Council, Naples, Italy.
Monica VitaleDepartment of Molecular Medicine and Medical Biotechnologies, University "Federico II", Naples, Italy ; CEINGE Biotecnologie Avanzate, Naples, Italy.
Nicola ZambranoDepartment of Molecular Medicine and Medical Biotechnologies, University "Federico II", Naples, Italy ; CEINGE Biotecnologie Avanzate, Naples, Italy.
Daniele SblatteroDepartment of Health Sciences and IRCAD, University of Eastern Piedmont, Novara, Italy.
Carla EspositoDepartment of Chemistry and Biology, University of Salerno, Salerno, Italy ; European Laboratory for the Investigation of Food-Induced Diseases (ELFID), University "Federico II", Naples, Italy.
University of Salerno · ITCeinge Biotecnologie Avanzate (Italy) · ITIstituto per il Sistema Produzione Animale in Ambiente Mediterraneo · ITNational Research Council · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCeliac disease is an inflammatory condition of the small intestine that affects genetically predisposed individuals after dietary wheat gliadin ingestion. Type 2-transglutaminase (TG2) activity seems to be responsible for a strong autoimmune response in celiac disease, TG2 being the main autoantigen. Several studies support the concept that celiac anti-TG2 antibodies may contribute to disease pathogenesis. Our recent findings on the ability of anti-TG2 antibodies to induce a rapid intracellular mobilization of calcium ions, as well as extracellular signal-regulated kinase phosphorylation, suggest that they potentially act as signaling molecules. In line with this concept, we have investigated whether anti-TG2 antibodies can induce phosphoproteome modification in an intestinal epithelial cell line. METHODS AND PRINCIPAL

findingsWe studied phosphoproteome modification in Caco-2 cells treated with recombinant celiac anti-TG2 antibodies. We performed a two-dimensional electrophoresis followed by specific staining of phosphoproteins and mass spectrometry analysis of differentially phosphorylated proteins. Of 14 identified proteins (excluding two uncharacterized proteins), three were hypophosphorylated and nine were hyperphosphorylated. Bioinformatics analyses confirmed the presence of phosphorylation sites in all the identified proteins and highlighted their involvement in several fundamental biological processes, such as cell cycle progression, cell stress response, cytoskeletal organization and apoptosis.

conclusionsIdentification of differentially phosphorylated proteins downstream of TG2-antibody stimulation suggests that in Caco-2 cells these antibodies perturb cell homeostasis by behaving as signaling molecules. We hypothesize that anti-TG2 autoantibodies may destabilize the integrity of the intestinal mucosa in celiac individuals, thus contributing to celiac disease establishment and progression. Since several proteins here identified in this study were already known as TG2 substrates, we can also suppose that transamidating activity and differential phosphorylation of the same targets may represent a novel regulatory mechanism whose relevance in celiac disease pathogenesis is still unexplored.

Indexed as

AntibodiesBlotting, WesternCaco-2 CellsCeliac DiseaseComputational BiologyElectrophoresis, Gel, Two-DimensionalGTP-Binding ProteinsHumansImage Processing, Computer-AssistedIntestinal MucosaPhosphoproteinsProtein Glutamine gamma Glutamyltransferase 2ProteomicsTransglutaminasesAntibodiesGTP-Binding ProteinsPhosphoproteinsProtein Glutamine gamma Glutamyltransferase 2Transglutaminases

Identifiers

PMID24391952
PMCPMC3877280
OpenAlexW2082375219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.